Pear Therapeutics and Crossroads Treatment Centers to Provide More Patients Access to Prescription Digital Therapeutics as Standard of Care for the Treatment of Substance Use Disorders
December 15, 2021
Expansion of Crossroads’s existing initiative with Pear’s prescription digital therapeutics (PDTs), reSET® and reSET-O®, has the potential to reach thousands of additional patients per month on their recovery journey across
Kentucky, New Jersey, Pennsylvania, and Virginia
- This expansion underscores shared commitment by Crossroads and Pear to expand access to innovative treatment options to fight against the addiction crisis
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005592/en/
According to a new report from the
“Crossroads is extremely excited to continue our cooperation with
“Having 24/7 access to cognitive behavioral therapy is a game changer for patients in recovery,” adds Wylie. “With access to patient-reported data, our clinicians can provide measurement-based care throughout a patient’s treatment journey to help improve outcomes. We feel that Pear is aligned with our vision to provide the most convenient, comprehensive, high-quality care, and we couldn’t be happier to extend our collaboration.”
Crossroads has been providing outpatient medication-assisted treatment (MAT) for more than 16 years to people suffering from OUD. At the forefront of treating patients with OUD, Crossroads is committed to bringing critical services to communities across the
“As the severity of the addiction crisis continues to increase, Pear’s expansion with Crossroads comes at a time when it’s more important than ever to provide people with SUD access to evidence-based treatments,” said
PDTs are a new therapeutic class that use software to treat serious disease. Like traditional medicines, PDTs are developed in a Good Manufacturing Practice-compliant environment; tested in randomized controlled trials to demonstrate safety and effectiveness; authorized by the FDA; and used under the supervision of a prescribing clinician1,2. Unlike traditional medicines, PDTs are designed to collect real-world data for use by prescribing clinicians and for population health management by payors and health systems.
reSET and reSET-O have been measured in real-world use and their therapeutic content has been studied in randomized controlled trials, with results published in peer-reviewed medical journals2,3 Pear recently released publications showing the potential for improved, real-world health outcomes and decreased treatment costs for patients using reSET-O4-11. Both products, which are adjunctive to outpatient counselling, provide patients with cognitive behavioral therapy, fluency training, and contingency management. Clinicians receive access to clinical dashboards to inform in-office and virtual visits.
reSET Important Safety Information
Indications for Use:
reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older,
It is intended to:
- increase abstinence from a patient’s substances of abuse during treatment, and
- increase retention in the outpatient treatment program.
Important Safety Information for Clinicians:
Warnings: reSET is intended for patients whose primary language is English with a reading level of 7th grade or above, and
Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.
reSET is not intended to be used as a stand-alone therapy for substance use disorder (SUD). reSET does not replace care by a licensed medical practitioner and is not intended to reduce the amount of face-to-face clinician time. reSET does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.
Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with substance use disorder also have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should engage in their normal care practices to monitor patients for medical problems and mental health disorders, including risk for harming others and/or themselves.
The long-term benefit of treatment with reSET on abstinence has not been evaluated in studies lasting beyond 12 weeks (90 days) in the SUD population. The ability of reSET to prevent potential relapse after treatment discontinuation has not been studied.
The effectiveness of reSET has not been demonstrated in patients currently reporting opioids as their primary substance of abuse.
reSET-O Important Safety Information
Indications for Use
reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older
Important Safety Information:
Warnings: reSET-O is intended for patients whose primary language is English with a reading level of 7th grade or above, and
reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner and is not intended to reduce the frequency or duration of in-person therapy. reSET-O does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.
Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should undertake standard of care to monitor patients for medical problems and mental health disease, including risk for harming others and/or themselves.
The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.
Crossroads is a behavioral healthcare company that has combined outpatient MAT, and measurement-based care for over 16 years. With more than 110 centers across 10 states, Crossroads exists to help people with SUDs and mental health illnesses get their lives back and strives to be the most convenient, comprehensive, high-quality behavioral health solution in the country. For more information about Crossroads, or to find a location near you, please visit our website at crossroadstreatmentcenters.com or call 800-805-6989.
Campbell ANC, Nunes EV,
Matthews AG, et al. Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry. 2014;171(6):683-690.
- Christensen DR, Landes RD, Jackson L, et al. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964-972. doi:10.1037/a0037496.
Yuri A. Maricich, MD, Xiaorui Xiong, PhD, Robert Gerwien, PhD, Alice Kuo, BA Fulton Velez, MD MBA, Bruce Imbert, MD PhD, Keely Boyer, MBA, Hilary F. Luderer, PhD, Stephen Braun, BA, Karren Williams, PhD (2020): Real-World evidence for a prescription digital therapeutic to treat Opioid Use Disorder, Journal of Current Medical Research and Opinion, DOI:10.1080/03007995.2020.1846023.
Fulton F. Velez, Sam Colman, Laura Kauffman, Charles Ruetsch& Kathryn Anastassopoulos(2020): Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2021.1840357
Weijia Wang, Nicole Gellings Lowe, Ali Jalali& Sean M. Murphy(2021) Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder, Journal of Medical Economics, 24:1, 61-68, DOI: 10.1080/13696998.2020.1858581
Yuri A. Maricich, Warren K. Bickel, Lisa A. Marsch, Kirstin Gatchalian, Jeffrey Botbyl& Hilary F. Luderer(2020) Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder, Current Medical Researchand Opinion, DOI: 10.1080/03007995.2020.1846022
Fulton F. Velez, Hilary F. Luderer, Robert Gerwien, Benjamin Parcher, Dylan Mezzio& Daniel C. Malone(2021) Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder, Postgraduate Medicine, DOI: 10.1080/00325481.2021.1884471
Fulton F. Velez, Charles Ruetsch& Yuri Maricich(2021) Evidence of long-term real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2021.193968
Fulton F. Velez& Daniel C. Malone(2021) Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder, Journal of Market Access & Health Policy, 9:1, DOI: 1080/20016689.2021.1966187
Yuri A. Maricich, Robert Gerwien, Alice Kuo, Daniel C. Malone& Fulton F. Velez(2021) Real-world use and clinical outcomes after 24 weeks of treatment with a prescription digital therapeutic for opioid use disorder, Hospital Practice, DOI: 1080/21548331.2021.1974243
Senior Director of Corporate Communications
Vice President of Marketing & Sales